Alzheimer's Association | GenomeWeb

Alzheimer's Association

The funding will support nine projects investigating why Alzheimer's disease disproportionately affects women versus men.

NEW YORK (GenomeWeb News) – The Alzheimer's Association and the Brin Wojcicki Foundation yesterday announced a partnership aimed at obtaining the whole-genome sequences of people with AD.

The figure comes from a report commissioned by proteomics firm Proteome Sciences, which, like a number of other protein biomarker firms including Quanterix, Rules-Based Medicine, and NextGen Sciences, has made AD a significant focus of its R&D and commercialization efforts.

The new guidelines mark the second publication in recent months to suggest that protein biomarkers be integrated into current definitions of Alzheimer's disease, though the new proposal explicitly calls for protein biomarkers to be used only in research settings.

The National Institute on Aging /Alzheimer's Association Guidelines for Alzheimer's Disease sees biomarker use in the clinic as a future prospect.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.